| Term 
 
        | what are the antiresorptive meds |  | Definition 
 
        | bisphosphonates, SERMs, calcitonin |  | 
        |  | 
        
        | Term 
 
        | anabolic therapy promotes waht is the med
 |  | Definition 
 
        | bone formation teriparatide
 |  | 
        |  | 
        
        | Term 
 
        | for kidney failure what vit d supplment can be used? why?
 |  | Definition 
 
        | DHT doesnt need 1a hydroxylation
 |  | 
        |  | 
        
        | Term 
 
        | what is currently not approved as Vit D supplment |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | enahnced Vit D clearence/ bad metabolism-> bone sofetning leads to |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what meds cause Vit d clereance what disease state?
 |  | Definition 
 
        | pheytoin, phoenoarbital, carbamazapine, rifampin; hepatic
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | bisphosphonates are P-C-P analogs of |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what are the 2 main bisphosphonates |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | which class of meds are incorporated into the bones |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | 1st generation BPS reduce resopriton by increasing _ |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | 2nd generation(amino) BPs reduce resorption by inhibiting 2 things |  | Definition 
 
        | osteoclast funciton and isoprenoid lipid ynth |  | 
        |  | 
        
        | Term 
 
        | BPs increase _ and reduce risk of |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | BPs are polar and high/low absoprtion from GI |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | esophageal distress, naseua |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | simple BPs form _ antimetabolites |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | which is mroe potent simple or Nitrogen BPs |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | nitrogen BPs inhibit _ synthase |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | isoprenoid lipids are needed for prenylation of _ |  | Definition 
 
        | small GTPases-ras, rho, rab |  | 
        |  | 
        
        | Term 
 
        | prenylates small GTPases are needed fro |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what two small GTPases affected by N containing BPs are anti-OP |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what GTPase inhibits osteoclast traffic? which deos apoptosis
 |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | raloxifene is estrogen agonist in _ antagonist in _
 |  | Definition 
 
        | bone breast and endometrial
 |  | 
        |  | 
        
        | Term 
 
        | raloxifene reduces _ type of fractures |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | raloxifene reduces _ cancer adn doesnt cause _ cancer |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | SERMs most common side afect |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what SERMs are not approved for OP |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what med is the recombinant of PTH |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | continuous exposure to PTH is bad bc causes |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | what populaitons is terparatide not reccomended |  | Definition 
 
        | children or paget's disease |  | 
        |  | 
        
        | Term 
 
        | do not use teriparatide in pateints with what disease state |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | max perriod of use of teriparatide |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | where is calcitonin synth |  | Definition 
 
        | prarfollical C cells of thyroid |  | 
        |  | 
        
        | Term 
 
        | calcitonin works on osteoclasts how- |  | Definition 
 
        | binds to receptr, reduces border surface osteoclasts and reduces acticity |  | 
        |  | 
        
        | Term 
 
        | calcitonin work on _ to promote Ca excretion |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | salmon calcitonin is more/less potent, longer lasting than human |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | side affects of calictonin |  | Definition 
 
        | rhinitis , nsal irriation |  | 
        |  | 
        
        | Term 
 
        | which med is given intrnasal |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | soluble  form of RANKL is formed by 2 ways |  | Definition 
 
        | secreted by 2 cells cleaved from osteoblast
 |  | 
        |  | 
        
        | Term 
 
        | what is the recepotr for RANKL where is it loacted
 |  | Definition 
 
        | RANK trnasmembran of osteoclast precursors
 |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | TRAF 6 carries signals thru what 2 cascades |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what is the natural inhibitor of RANKL |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what is a human Mab  medicaiton agaisnt RANKL |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | what does denosumab act like |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Denosumab is used for _ OP in what population |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | MOA of denosumab is 2 things |  | Definition 
 
        | reduces resorption suppresses bone turnover
 |  | 
        |  | 
        
        | Term 
 
        | dosing fro denosumab how is it admin
 |  | Definition 
 
        | 60 mg q 6 months for 3 yrs subQ
 |  | 
        |  | 
        
        | Term 
 
        | some dise affects of denosumab |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | denosumab is contraindicated in - 5 |  | Definition 
 
        | preggo hypocalcemia
 serious infections
 liverr disease
 children
 |  | 
        |  | 
        
        | Term 
 
        | what is the transdermal gel med |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | androgens see increase BMD in 2 pops |  | Definition 
 
        | men with hypogonads OP women
 |  | 
        |  | 
        
        | Term 
 
        | testosterone contraindicated in men with |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | weight gain, acne, testical atrophy |  | 
        |  | 
        
        | Term 
 
        | Ca supplements readily availabel where |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | absoprtion of Ca increases/decreases with tablet size increase |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | constipation, gas, upset stomach |  | 
        |  | 
        
        | Term 
 
        | Ca supplment can decrease absorption of - 3 things |  | Definition 
 
        | iron tetracyclines
 phenytoin
 |  | 
        |  |